Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

Article  PubMed  Google Scholar 

Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

Article  PubMed  Google Scholar 

Ma H, Davarifar A, Amengual JE. The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). Curr Hematologic Malignancy Rep. 2018;13:13–24.

Article  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–65.

Article  CAS  PubMed  Google Scholar 

Richardson NC, Kasamon YL, Chen H, de Claro RA, Ye J, Blumenthal GM, et al. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. Oncologist. 2019;24:e180–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamoun M, Kadin ME, Martin PJ, Nettleton J, Hansen JA. A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. J Immunol. 1981;127:987–91.

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Font J, Garcia-Carrasco M, Calvo J, Places L, Padilla O, et al. High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjogren’s syndrome. Rheumatol (Oxf). 2001;40:1056–9.

Article  CAS  Google Scholar 

Braun M, Muller B, ter Meer D, Raffegerst S, Simm B, Wilde S, et al. The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion. J Innate Immun. 2011;3:420–34.

Article  CAS  PubMed  Google Scholar 

Li Y, Ruth JH, Rasmussen SM, Athukorala KS, Weber DP, Amin MA, et al. Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6. Arthritis Rheumatol. 2020;72:1505–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Li Y, Qiu W, Bell BA, Dvorina N, Baldwin WM 3rd, et al. Targeting CD6 for the treatment of experimental autoimmune uveitis. J Autoimmun. 2018;90:84–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Singer NG, Whitbred J, Bowen MA, Fox DA, Lin F. CD6 as a potential target for treating multiple sclerosis. Proc Natl Acad Sci USA. 2017;114:2687–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dogra S, Uprety S, Suresh SH. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opin Biol Ther. 2017;17:395–402.

Article  CAS  PubMed  Google Scholar 

Parthasaradhi A. Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients. J Clin Diagn Res. 2016;10:WD01–3.

PubMed  PubMed Central  Google Scholar 

Dogra S, Shabeer D, Rajagopalan M. Anti-CD6 mAbs for the treatment of psoriasis. Expert Opin Biol Ther. 2020;20:1215–22.

Article  CAS  PubMed  Google Scholar 

Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol. 2014;38:768–75.

Article  PubMed  PubMed Central  Google Scholar 

Garcia Santana CA, Tung JW, Gulnik S. Human treg cells are characterized by low/negative CD6 expression. Cytom A. 2014;85:901–8.

Article  Google Scholar 

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koster J, DeSouza TA, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016;30:183.

Article  CAS  PubMed  Google Scholar 

Gill RPK, Gantchev J, Martinez Villarreal A, Ramchatesingh B, Netchiporouk E, Akilov OE, et al. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma. Cells. 2022;11:593.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20:323–42.

Article  CAS  PubMed  Google Scholar 

Horwitz S, O’Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288–98.

Article  CAS  PubMed  Google Scholar 

Cattoretti G. MYC expression and distribution in normal mature lymphoid cells. J Pathol. 2013;229:430–40.

Article  CAS  PubMed  Google Scholar 

Alzona M, Jack HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol. 1994;153:2861–7.

Article  CAS  PubMed  Google Scholar